Targeting ultra-processed foods for prevention of type 2 diabetes: state of the evidence and future directions
Mendoza K, Barquera S, Tobias DK
Diabetologia. Pub. online 18 Jan 2025.
Leggi
Breaking news
AIFA: Parere favorevole all’ammissione alla rimborsabilità del medicinale «Baqsimi» per il trattamento dell’ipoglicemia severa
17/12/2024
Leggi
Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
Lingvay I, Benamar M, Chen L, et al.
Diabetologia. Pub. online 17 Jan 2025.
Leggi
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist
le Roux CW, Steen O, Lucas KJ, et al.
Diabetes Obes Metab. Pub. online 16 Jan 2025.
Leggi
Three-year follow-up after antiviral treatment in new-onset type 1 diabetes: results from the diabetes virus detection and intervention trial
Mynarek IM, Krogvold L, Mørk FB, et al.
Diabetes Care. 2025:dc242121.
Leggi
Hypertensive disorders of pregnancy and gestational diabetes mellitus and predicted risk of maternal cardiovascular disease 10-14 years after delivery: a prospective cohort
Venkatesh KK, Grobman WA, Wu J, et al.
Diabet Med. 2025:e15516.
Leggi
The Virtual DCCT: adding continuous glucose monitoring to a landmark clinical trial for prediction of microvascular complications
Kovatchev BP, Lobo B, Fabris C, et al.
Diabetes Technol Ther. Pub. online 8 Jan 2025.
Leggi
Genetic predisposition to low-density lipoprotein cholesterol and incident type 2 diabetes
Ravi A, Koyama S, Cho SMJ, et al.
JAMA Cardiol. Pub. online 15 Jan 2025.
Leggi
Association of changes in the type 2 diabetes and MASLD/related SLD status with risk of developing cardiovascular disease
Matsubayashi Y, Fujihara K, Khin L, et al.
Diabetes Obes Metab. Pub. online 15 Jan 2025.
Leggi
Calorie (energy) labelling for changing selection and consumption of food or alcohol
Clarke N, Pechey E, Shemilt I, et al.
Cochrane Database Syst Rev. 2025;1:CD014845.
Leggi